Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the ...
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic ...
Le Lézard16m
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year ...
Le Lézard11m
Intellicheck to Announce Fourth Quarter and Full Year 2024 Financial Results
Intellicheck, Inc. , an industry-leading identity company delivering proprietary on-demand digital and physical identity validation solutions, will report financial results on March 20, 2025 for the ...
ABP News on MSN19m
The Asymptomatic Stages Of Kidney Disease And Their Impact On Delayed Diagnosis
By: Dr. Suresh D.R., Chief of Laboratory - Centralab Metropolis, Karnataka, and Regional COL - Andhra Pradesh and Telangana, ...